In colorectal cancer, the mitogen-activated protein kinase (MAPK) pathway is a commonly mutated pathway with 35–40% of patients having an activating mutation in KRAS and 5–10% of patients having an activating mutation in BRAF [21, 22]. Here, WNK2 is linked to colorectal cancer.